Recent Finacing
Recent Raise
Myosana develops a non-viral gene-delivery platform that targets skeletal and cardiac muscle to deliver full-length genes (including dystrophin), enable repeat dosing, and reduce viral-vector immunogenicity for neuromuscular diseases.
